MUSC Hollings Cancer Center is led by a team of renowned physicians, researchers, and administrators who have trained and served in prominent positions at some of the country’s top cancer centers and academic medical institutions. These leaders provide vision, guidance, and expertise across all of the center’s programs and initiatives.

Hollings also benefits from an external Advisory Board comprised of business, government, and lay community leaders as well as an External Scientific Advisory Board (ESAB) consisting of nationally-recognized leaders in cancer research and treatment. Together, these teams are charged with establishing Hollings as one of the country’s top centers for cancer care.

Center Director

Dr. Raymond DuBois wearing a white physician's coat

Raymond N. DuBois, M.D., Ph.D.

Hollings Cancer Center 124J

Dr. DuBois holds dual roles as director of MUSC Hollings Cancer Center, an appointment he began in August 2020, and as dean of the College of Medicine, a position he has held since he joined MUSC in 2016. As a physician-scientist, Dr. DuBois is passionate about cancer research and patient-centered care, and his expertise guides Hollings forward in both areas.

An international leader in the cancer community, Dr. DuBois has more than 30 years of research experience and over 20 years of concurrent leadership experience, including senior roles at MD Anderson Cancer Center and Vanderbilt-Ingram Cancer Center. He was elected to the National Academy of Medicine in 2019, which places him in the company of an elite group of internationally renowned scientists and doctors.

Center Leadership

Donna Berrier 

Donna Berrier, MPA

Associate Director, Administration

Hollings Cancer Center 118K

Ms. Berrier joined Hollings as the associate director of administration in 2017. In her role, Ms. Berrier works closely with the director and members of senior and programmatic leadership to build and support the research infrastructure crucial to Hollings’ mission. She identifies new cancer research opportunities and develops resources to support these and existing efforts. Ms. Berrier has over a decade of experience working with NCI-designated cancer centers.


Dr. Marvella Ford 

Marvella E. Ford, Ph.D.

Associate Director, Population Science and Cancer Disparities

Bioengineering 103A

A professor of public health sciences, Dr. Ford oversees the center’s effort to address the state’s critical cancer disparities while implementing initiatives that integrate expertise in population sciences among the center’s cancer control researchers. Through community outreach and educational programs, Dr. Ford and her team work with minority leaders throughout the state to build bi-directional, trusting, and long-lasting partnerships, which are critical to Hollings investigators in tailoring culturally and contextually knowledgeable cancer interventions. She also works with the South Carolina Department of Health and Environmental Control to implement cancer-focused initiatives, including the State Cancer Plan.


Dr. Denis Guttridge 

Denis C. Guttridge, Ph.D.

Associate Director, Translational Science

Drug Discovery 305

Dr. Guttridge joined MUSC in 2018 as the Hollings Cancer Center associate director of translational science and the director of the Charles P. Darby Children’s Research Institute. Dr. Guttridge holds a robust research funding portfolio and has authored more than 130 peer-reviewed publications. He has received numerous recognitions for his contributions to cancer research and his dedication to fostering multidisciplinary and collaborative science.


Dr. Chanita Hughes-Halbert 

Chanita A. Hughes-Halbert, Ph.D.

Associate Director, Education and Training

Bioengineering 103D

Dr. Hughes-Halbert is a professor of psychiatry and behavioral sciences. As associate director, she ensures the education and training opportunities for pre- and post-doctoral students as well as junior faculty within the Hollings Cancer Center are well-structured, coordinated across multiple initiatives, effective, and promote transdisciplinary collaborations.


Dr. Craig Lockhart 

Craig Lockhart, M.D.

Associate Director, Clinical Science
Chief, Oncology Integrated Center of Clinical Excellence


Dr. Lockhart is the chief of the Division of Hematology & Oncology in the MUSC Department of Medicine. With over 20 years of experience conducting clinical trials, a key part of his role as associate director is facilitating efforts to bring scientific discoveries from Hollings' laboratories into clinical application through clinical trials. As the Oncology Integrated Center of Clinical Excellence (ICCE) chief, Dr. Lockhart oversees the clinical activities and performance of Hollings and executes strategies for program development and growth.


Pam Murphy 

Pamela K. Murphy, Ph.D.

Associate Director, Clinical Services
Administrator, Oncology Integrated Center of Clinical Excellence

Hollings Cancer Center 118E

As associate director of clinical services, Dr. Murphy participates in strategic planning and implementation of priority initiatives that align oncology clinical operations with cancer center research priorities. In her role as the Oncology Integrated Center of Clinical Excellence (ICCE) administrator, she is responsible for driving the MUSC Health system-wide oncology ICCE strategy, oversight of day-to-day clinical oncology operations, performance & growth of oncology clinical services, and ensuring academic integration. 


Dr. Steven Rosenzweig 

Steven A. Rosenzweig, Ph.D.

Associate Director, Shared Resources

Basic Sciences 313G

Dr. Rosenzweig is a professor of cell and molecular pharmacology. As associate director, he oversees the ongoing evaluation, development, and growth of Hollings-supported shared research resources. These shared facilities provide access to critical technologies, services, and consultation that enhance scientific interaction and productivity of cancer center members.


Dr. Xue-Zhong Yu 

Xue-Zhong Yu, M.D.

Associate Director, Basic Science

Hollings Cancer Center 350

Dr. Yu is a professor with a primary appointment in the Department of Microbiology & Immunology and a secondary appointment in the Division of Hematology/Oncology in the Department of Medicine, where he holds a SmartState Endowed Chair in Cancer Stem Cell Biology and Therapy. In this associate director role, Dr. Yu identifies and shapes the trajectory of new scientific directions and integrates basic science discoveries across multiple discipline areas, helping to accelerate translational advances into the clinic.